Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting

– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter –

– Progression of CTEV into human study supported by positive preclinical results presented at multiple scientific meetings and in a recent publication –